Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to serious pulmonary and non-pulmonary disease using its patented iSPERSE™ technology, announced upcoming changes to its Board of Directors.

• Chris Cabell, M.D. is appointed to the Pulmatrix Board of Directors effective June 23, 2020
• Steven Gillis, Ph.D. has resigned from the Pulmatrix Board of Directors effective September 1, 2020

"First, I want to thank Steve for almost eleven years of strategic guidance as a Director. All of us at Pulmatrix deeply appreciate Steve and everything he has done to help Pulmatrix advance its mission to commercialize transformational medicines for patients," said Ted Raad, Chief Executive Officer of Pulmatrix. Ted Raad continued, "With a diverse product pipeline entering various stages of global clinical development, I am pleased to announce the appointment of Dr. Chris Cabell to the Board of Directors. Dr. Cabell's extensive research and development experience will be a resource for strategic guidance as we look to advance multiple clinical programs in the future."

Dr. Chris Cabell is the Executive Vice President, Head of Research and Development, and Chief Medical Officer at Arena Pharmaceuticals. Prior to joining Arena, Dr. Cabell spent 10 years at Quintiles Inc and QuintilesIMS in a variety of management positions including Chief Medical and Scientific Officer, Global Head of Medical and Project Management, and Global Head of Business Development. Prior to joining Quintiles, Dr. Cabell was on faculty at Duke University School of Medicine in the Division of Cardiology. Dr. Cabell is a Fellow of the American College of Cardiology and has over 100 peer reviewed publications including in the New England Journal of Medicine, JAMA, and Annals of Internal Medicine. Board certified in both internal medicine and cardiovascular diseases, Dr. Cabell is a honors graduate of Pennsylvania State University and Duke University, earning both his Medical Degree and a Masters in Health Sciences from the latter.

Dr. Cabell said, "I believe that the products in the Pulmatrix pipeline have the potential to address significant unmet needs for patients with respiratory and other diseases. I look forward to working with the Board of Directors and management to help advance this important pipeline of products."

About Pulmatrix

Pulmatrix is a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and non-pulmonary disease using its patented iSPERSE™ technology. The Company's proprietary product pipeline is initially focused on advancing treatments for serious lung diseases, including Pulmazole, an inhaled anti-fungal for patients with allergic bronchopulmonary aspergillosis ("ABPA"), and PUR1800, a narrow spectrum kinase inhibitor in lung cancer. Pulmatrix's product candidates are based on iSPERSE™, its proprietary engineered dry powder delivery platform, which seeks to improve therapeutic delivery to the lungs by maximizing local concentrations and reducing systemic side effects to improve patient outcomes.